1 Failure to Induce Global/Clinical Remission |
11 |
2387 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.86 [0.82, 0.89] |
1.1 Dose of 5‐ASA: < 2 g |
3 |
231 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.92 [0.84, 1.02] |
1.2 Dose of 5‐ASA : 2 ‐ 2.9 g |
8 |
956 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.88 [0.82, 0.94] |
1.3 Dose of 5‐ASA: >or=3 g |
8 |
1200 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.83 [0.77, 0.88] |
2 Failure to Induce Global/Clinical Remission or Improvement |
14 |
2256 |
Risk Ratio (M‐H, Random, 95% CI) |
0.68 [0.61, 0.75] |
2.1 Dose of 5‐ASA: < 2 g |
3 |
231 |
Risk Ratio (M‐H, Random, 95% CI) |
0.79 [0.64, 0.97] |
2.2 Dose of 5‐ASA: 2 ‐ 2.9 g |
10 |
877 |
Risk Ratio (M‐H, Random, 95% CI) |
0.77 [0.67, 0.88] |
2.3 Dose of 5‐ASA: >or=3 g |
9 |
1148 |
Risk Ratio (M‐H, Random, 95% CI) |
0.57 [0.51, 0.65] |
3 Failure to Induce Endoscopic Remission |
4 |
1154 |
Risk Ratio (M‐H, Random, 95% CI) |
0.77 [0.67, 0.89] |
3.1 Dose of 5‐ASA: < 2 g |
1 |
122 |
Risk Ratio (M‐H, Random, 95% CI) |
0.85 [0.64, 1.14] |
3.2 Dose of 5‐ASA : 2 ‐ 2.9 g |
3 |
393 |
Risk Ratio (M‐H, Random, 95% CI) |
0.86 [0.70, 1.05] |
3.3 Dose of 5‐ASA: >or=3 g |
4 |
639 |
Risk Ratio (M‐H, Random, 95% CI) |
0.70 [0.56, 0.87] |
4 Failure to Induce Endoscopic Remission or Improvement |
4 |
416 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.71 [0.59, 0.86] |
4.1 Dose of 5‐ASA: < 2 g |
0 |
0 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
4.2 Dose of 5‐ASA : 2 ‐ 2.9 g |
3 |
265 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.73 [0.58, 0.92] |
4.3 Dose of 5‐ASA: >or=3 g |
2 |
151 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.69 [0.49, 0.96] |
5 Development of Any Adverse Event |
8 |
1218 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.95 [0.85, 1.07] |
5.1 Dose of 5‐ASA: < 2 g |
1 |
30 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.26 [0.74, 2.13] |
5.2 Dose of 5‐ASA : 2 ‐ 2.9 g |
5 |
377 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.04 [0.82, 1.33] |
5.3 Dose of 5‐ASA: >or=3 g |
5 |
811 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.91 [0.80, 1.05] |
6 Withdrawal from Study due to Adverse Event |
13 |
2372 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.72 [0.54, 0.97] |
6.1 Dose of 5‐ASA: < 2 g |
3 |
231 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.55 [0.19, 1.63] |
6.2 Dose of 5‐ASA : 2 ‐ 2.9 g |
9 |
926 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.13 [0.65, 1.94] |
6.3 Dose of 5‐ASA: >or=3 g |
9 |
1215 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.59 [0.41, 0.87] |
7 Withdrawal from Study due to Adverse Event (sensitivity analysis) |
12 |
2091 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.88 [0.62, 1.24] |
7.1 Dose of 5‐ASA: < 2 g |
3 |
231 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.55 [0.19, 1.63] |
7.2 Dose of 5‐ASA : 2 ‐ 2.9 g |
9 |
926 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.13 [0.65, 1.94] |
7.3 Dose of 5‐ASA: >or=3 g |
8 |
934 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.78 [0.47, 1.26] |
8 Exclusions and Withdrawals after Entry |
15 |
2529 |
Risk Ratio (M‐H, Random, 95% CI) |
0.61 [0.51, 0.72] |
8.1 Dose of 5‐ASA: < 2 g |
3 |
231 |
Risk Ratio (M‐H, Random, 95% CI) |
0.64 [0.42, 0.98] |
8.2 Dose of 5‐ASA : 2 ‐ 2.9 g |
11 |
1014 |
Risk Ratio (M‐H, Random, 95% CI) |
0.70 [0.53, 0.92] |
8.3 Dose of 5‐ASA: >or=3 g |
10 |
1284 |
Risk Ratio (M‐H, Random, 95% CI) |
0.52 [0.41, 0.66] |